Spyre Therapeutics
SYRE
119 hedge funds and large institutions have $1.51B invested in Spyre Therapeutics in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 43 increasing their positions, 24 reducing their positions, and 18 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 24
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
28% more capital invested
Capital invested by funds: $1.18B → $1.51B (+$328M)
11% more funds holding
Funds holding: 107 → 119 (+12)
1.68% more ownership
Funds ownership: 99.22% → 100.89% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
53% less call options, than puts
Call options by funds: $18K | Put options by funds: $38K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$35.3M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$31.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$19.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.8M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$34.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$21.1M |
| 3 |
Goldman Sachs
New York
|
-$20.2M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$15.7M |
| 5 |
FTM
First Turn Management
Del Mar,
California
|
-$10.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IHAM
126
Integral Health Asset Management
New York
| – | -$2.35M | -100,000 | Closed |
|
127
Norges Bank
Oslo,
Norway
| – | -$1.67M | -70,843 | Closed |
|
|
JF
128
Jump Financial
Chicago,
Illinois
| – | -$1.53M | -64,900 | Closed |
|
|
BCM
129
Bridgeway Capital Management
Houston,
Texas
| – | -$849K | -36,100 | Closed |
|
|
AGM
130
Alpine Global Management
New York
| – | -$796K | -33,858 | Closed |
|
|
EI
131
EAM Investors
Solana Beach,
California
| – | -$422K | -17,938 | Closed |
|
132
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$298K | -12,672 | Closed |
|
|
ACM
133
Aquatic Capital Management
Chicago,
Illinois
| – | -$277K | -11,800 | Closed |
|
|
VF
134
Virtu Financial
New York
| – | -$259K | -11,016 | Closed |
|
135
Pacer Advisors
Malvern,
Pennsylvania
| – | -$8.98K | -382 | Closed |
|
136
Simplex Trading
Chicago,
Illinois
| – | -$1K | -64 | Closed |
|
|
C
137
Covestor
London,
United Kingdom
| – | +$84 | +3 | New |
|
SYRE Hedge Fund Activity: Q3 2024 in Review
119 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q3 2024, worth a combined $1.51B — up 28% from $1.18B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SYRE positions and 18 closed out — a net gain of 12 holders — while 43 added to existing stakes and 24 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $35.3M. The largest seller was Avoro Capital Advisors, cutting an estimated $34.5M.
- 119 institutional investors held Spyre Therapeutics (SYRE) as of Q3 2024, up from 107 in Q2 2024.
- Funds reported $1.51B of Spyre Therapeutics stock for Q3 2024, up 28% quarter-over-quarter.
- 30 funds opened new Spyre Therapeutics positions in Q3 2024 and 18 closed out, a net change of +12 holders.
- The largest Spyre Therapeutics buyer in Q3 2024 was Paradigm Biocapital Advisors, an estimated $35.3M added.
- The largest Spyre Therapeutics seller in Q3 2024 was Avoro Capital Advisors, an estimated $34.5M sold.
Based on aggregated 13F filings for Q3 2024.